Purchase of Nanobodies and epitope mapping for grant funded project

The very important time constrains (before 20th of March 2026) attached to the awarded grant finance, for our specific objective, This supplier expertise with expressing our nanobody sequences in different formats, their speed, competitive pricing and MHRA’s prior in house validation of nanobody products made by this supplier , makes this supplier in our view the only provider that can realistically meet our request within the allocated timelines. Protein production can be outsourced from several commercial entities, but the trade for companies that have relevant and ample experience in nanobody expression, at small scale, in a cost-effective and time-saving manner to fulfil our request is limited. Further, the timeline to complete the objectives of the project with the awarded grant finance translates into the inability to search, outsource, trial and validate the suitability of nanobodies produced by other suppliers unknown to MHRA, significantly narrowing feasible possibilities.